EP1883419A4 - Agonistes vis-a-vis du recepteur peptidique de type glucagon 1 (glp-1) et procedes pharmacologiques d'utilisation - Google Patents
Agonistes vis-a-vis du recepteur peptidique de type glucagon 1 (glp-1) et procedes pharmacologiques d'utilisationInfo
- Publication number
- EP1883419A4 EP1883419A4 EP06759154A EP06759154A EP1883419A4 EP 1883419 A4 EP1883419 A4 EP 1883419A4 EP 06759154 A EP06759154 A EP 06759154A EP 06759154 A EP06759154 A EP 06759154A EP 1883419 A4 EP1883419 A4 EP 1883419A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- glp
- glucagon
- peptide
- receptor agonists
- pharmacological methods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Emergency Medicine (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67872305P | 2005-05-06 | 2005-05-06 | |
PCT/US2006/017411 WO2006121860A2 (fr) | 2005-05-06 | 2006-05-05 | Agonistes vis-a-vis du recepteur peptidique de type glucagon 1 (glp-1) et procedes pharmacologiques d'utilisation |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1883419A2 EP1883419A2 (fr) | 2008-02-06 |
EP1883419A4 true EP1883419A4 (fr) | 2010-08-04 |
Family
ID=37397130
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP06759154A Withdrawn EP1883419A4 (fr) | 2005-05-06 | 2006-05-05 | Agonistes vis-a-vis du recepteur peptidique de type glucagon 1 (glp-1) et procedes pharmacologiques d'utilisation |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1883419A4 (fr) |
JP (1) | JP2008539735A (fr) |
CA (1) | CA2607566A1 (fr) |
WO (1) | WO2006121860A2 (fr) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2666193A1 (fr) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Imidazolidin-2,4-dione arylaminoaryl-alkyl-substituee, son procede de fabrication, medicament contenant ce compose et son utilisation |
EP2025674A1 (fr) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament |
EP2200626A4 (fr) * | 2007-09-07 | 2012-02-15 | Ipsen Pharma Sas | Analogues d'exendine-4 et exendine-3 |
DE102007063671A1 (de) | 2007-11-13 | 2009-06-25 | Sanofi-Aventis Deutschland Gmbh | Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
KR101277560B1 (ko) * | 2007-12-11 | 2013-06-25 | 카딜라 핼쓰캐어 리미티드 | 글루카곤 안타고니스트 활성 및 glp-1 아고니스트 활성의 펩티드 유사체 |
UY31968A (es) | 2008-07-09 | 2010-01-29 | Sanofi Aventis | Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos |
WO2010068601A1 (fr) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant |
KR101809024B1 (ko) | 2009-07-13 | 2017-12-14 | 질랜드 파마 에이/에스 | 아실화 글루카곤 유사체 |
EP2470552B1 (fr) | 2009-08-26 | 2013-11-13 | Sanofi | Nouveaux hydrates de fluoroglycoside hétéroaromatiques cristallins, produits pharmaceutiques comprenant ces composés et leur utilisation |
TW201124391A (en) | 2009-10-20 | 2011-07-16 | Lundbeck & Co As H | 2-substituted-ethynylthiazole derivatives and uses of same |
WO2011107494A1 (fr) | 2010-03-03 | 2011-09-09 | Sanofi | Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation |
AR080592A1 (es) * | 2010-03-26 | 2012-04-18 | Lilly Co Eli | Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso |
DE102010015123A1 (de) | 2010-04-16 | 2011-10-20 | Sanofi-Aventis Deutschland Gmbh | Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
US8901114B2 (en) | 2011-03-08 | 2014-12-02 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
WO2012120056A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés oxathiazine tétra-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation |
EP2683699B1 (fr) | 2011-03-08 | 2015-06-24 | Sanofi | Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation |
US20120282255A1 (en) * | 2011-04-07 | 2012-11-08 | Greg Plucinski | Methods and compositions for the treatment of alcoholism and alcohol dependence |
AU2012255116B2 (en) | 2011-05-18 | 2017-05-25 | Mederis Diabetes, Llc | Improved peptide pharmaceuticals |
AU2012255119B2 (en) * | 2011-05-18 | 2017-04-20 | Mederis Diabetes, Llc | Improved peptide pharmaceuticals for insulin resistance |
EP2567959B1 (fr) | 2011-09-12 | 2014-04-16 | Sanofi | Dérivés d'amide d'acide 6-(4-hydroxy-phényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase |
WO2013037390A1 (fr) | 2011-09-12 | 2013-03-21 | Sanofi | Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase |
EP2760862B1 (fr) | 2011-09-27 | 2015-10-21 | Sanofi | Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique utilisés comme inhibiteurs de kinase |
BR112014027348B1 (pt) * | 2012-05-03 | 2022-12-20 | Zealand Pharma A/S | Compostos agonistas duplos gip-glp-1 e métodos |
FR2991055B1 (fr) * | 2012-05-22 | 2014-06-13 | C2 Diagnostics | Dispositif de connexion fluidique pour appareils d'analyse biologique, composant fluidique adapte et appareil d'analyse biologique ainsi equipe; |
CN109456400A (zh) | 2012-07-23 | 2019-03-12 | 西兰制药公司 | 胰高血糖素类似物 |
TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
AU2013329077A1 (en) * | 2012-10-11 | 2015-04-23 | Tufts University | Compositions and methods for sustained delivery of glucagon-like peptide (GLP-1) receptor agonist therapeutics |
US10005817B2 (en) | 2012-11-20 | 2018-06-26 | Eumederis Pharmaceuticals, Inc. | Peptide pharmaceuticals |
CA2891931A1 (fr) | 2012-11-20 | 2014-05-30 | Mederis Diabetes, Llc | Produits pharmaceutiques peptidiques ameliores pour la resistance a l'insuline |
PT3057984T (pt) | 2013-10-17 | 2018-10-24 | Boehringer Ingelheim Int | Análogos de glucagon acilados |
US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
JP6682432B2 (ja) | 2013-11-06 | 2020-04-15 | ジーランド ファーマ アクティーゼルスカブ | Gip−glp−1デュアルアゴニスト化合物及び方法 |
EP3066117B1 (fr) | 2013-11-06 | 2019-01-02 | Zealand Pharma A/S | Composés agonistes triples glucagon-glp-1-gip |
AU2015266854B2 (en) | 2014-05-28 | 2020-03-26 | Mederis Diabetes, Llc | Improved peptide pharmaceuticals for insulin resistance |
EP3212218B1 (fr) | 2014-10-29 | 2021-06-30 | Zealand Pharma A/S | Composés agonistes de gip et procédés associés |
CN107636010B (zh) | 2015-04-16 | 2021-10-01 | 西兰制药公司 | 酰化胰高血糖素类似物 |
US11541028B2 (en) | 2018-01-03 | 2023-01-03 | Altimmune Inc. | Peptide pharmaceuticals for treatment of NASH and other disorders |
EP3768294A4 (fr) | 2018-03-23 | 2022-05-04 | Carmot Therapeutics, Inc. | Modulateurs de récepteurs couplés à la protéine |
LT4122954T (lt) | 2018-04-05 | 2024-06-25 | Sun Pharmaceutical Industries Limited | Nauji glp-1 analogai |
CN108676084B (zh) * | 2018-05-31 | 2021-12-03 | 长春百克生物科技股份公司 | 艾塞那肽的修饰物及其应用 |
CN109021093B (zh) * | 2018-08-29 | 2021-09-07 | 上海生物制品研究所有限责任公司 | 聚乙二醇修饰的glp-1衍生物及其药用盐 |
CN111410687B (zh) * | 2020-02-21 | 2023-06-27 | 成都奥达生物科技有限公司 | 一种长效glp-1化合物 |
CN113461785B (zh) * | 2021-04-13 | 2022-10-14 | 湖南中晟全肽生化有限公司 | Glp-1受体激动剂及其应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999043707A1 (fr) * | 1998-02-27 | 1999-09-02 | Novo Nordisk A/S | Derives de glp-1 modifies a l'extremite n-terminale |
WO2000066629A1 (fr) * | 1999-04-30 | 2000-11-09 | Amylin Pharmaceuticals, Inc. | Exendines modifiees et agonistes de l'exendine |
WO2004022004A2 (fr) * | 2002-09-06 | 2004-03-18 | Bayer Pharmaceuticals Corporation | Agonistes modifies du recepteur glp-1 et leurs procedes pharmacologiques d'utilisation |
WO2004093823A2 (fr) * | 2003-03-19 | 2004-11-04 | Eli Lilly And Company | Composes glp-1 a liaison polyethylene glycol |
US6864069B2 (en) * | 2001-10-05 | 2005-03-08 | Bayer Pharmaceuticals Corporation | Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5545618A (en) * | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
US6514500B1 (en) * | 1999-10-15 | 2003-02-04 | Conjuchem, Inc. | Long lasting synthetic glucagon like peptide {GLP-!} |
WO2004029081A2 (fr) * | 2002-09-25 | 2004-04-08 | Theratechnologies Inc. | Peptides glp-1 modifies a activite biologique accrue |
-
2006
- 2006-05-05 JP JP2008510259A patent/JP2008539735A/ja active Pending
- 2006-05-05 CA CA002607566A patent/CA2607566A1/fr not_active Abandoned
- 2006-05-05 WO PCT/US2006/017411 patent/WO2006121860A2/fr active Application Filing
- 2006-05-05 EP EP06759154A patent/EP1883419A4/fr not_active Withdrawn
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999043707A1 (fr) * | 1998-02-27 | 1999-09-02 | Novo Nordisk A/S | Derives de glp-1 modifies a l'extremite n-terminale |
WO2000066629A1 (fr) * | 1999-04-30 | 2000-11-09 | Amylin Pharmaceuticals, Inc. | Exendines modifiees et agonistes de l'exendine |
US6864069B2 (en) * | 2001-10-05 | 2005-03-08 | Bayer Pharmaceuticals Corporation | Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use |
WO2004022004A2 (fr) * | 2002-09-06 | 2004-03-18 | Bayer Pharmaceuticals Corporation | Agonistes modifies du recepteur glp-1 et leurs procedes pharmacologiques d'utilisation |
WO2004093823A2 (fr) * | 2003-03-19 | 2004-11-04 | Eli Lilly And Company | Composes glp-1 a liaison polyethylene glycol |
Non-Patent Citations (2)
Title |
---|
ROBERTS M J ET AL: "Chemistry for peptide and protein PEGylation", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER BV, AMSTERDAM, NL LNKD- DOI:10.1016/S0169-409X(02)00022-4, vol. 54, no. 4, 17 June 2002 (2002-06-17), pages 459 - 476, XP002293146, ISSN: 0169-409X * |
VERONESE F M: "Peptide and protein PEGylation - a review of problems and solutions", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB LNKD- DOI:10.1016/S0142-9612(00)00193-9, vol. 22, no. 5, 1 March 2001 (2001-03-01), pages 405 - 417, XP004227886, ISSN: 0142-9612 * |
Also Published As
Publication number | Publication date |
---|---|
WO2006121860A3 (fr) | 2007-04-12 |
JP2008539735A (ja) | 2008-11-20 |
CA2607566A1 (fr) | 2006-11-16 |
WO2006121860A2 (fr) | 2006-11-16 |
EP1883419A2 (fr) | 2008-02-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1883419A4 (fr) | Agonistes vis-a-vis du recepteur peptidique de type glucagon 1 (glp-1) et procedes pharmacologiques d'utilisation | |
AU2003273300A8 (en) | Modified glp-1 receptor agonists and their pharmacological methods of use | |
HK1073117A1 (en) | Peptides acting as both glp-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use | |
HK1206241A1 (en) | Glucagon-like peptide 1 (glp-1) pharmaceutical formulations 1(glp-1) | |
ZA200605721B (en) | The glucagon-like peptide-1 receptor agonists, the preparation and the use of the same | |
IL177066A0 (en) | Combined use of a glp-1 agonist and gastrin compounds | |
AU2003239478A8 (en) | Modified glucagon-like peptide-1 analogs | |
IL189670A0 (en) | Trail receptor 2 polypeptides and antibodies | |
ZA200705674B (en) | Peptides with neuropeptide-2 receptor (Y2R) agonist activity | |
AU5716901A (en) | G protein coupled receptor (gpcr) agonists and antagonists and methods of activating and inhibiting gpcr using the same | |
EP1583503A4 (fr) | Agonistes multivalents de recepteur beta de lymphotoxine et leurs applications therapeutiques | |
IL178254A0 (en) | Receptor coupling agents and therapeutic uses thereof | |
IL197776A0 (en) | Il-17a/f heterodimeric polypeptides and therapeutic uses thereof | |
ZA200710699B (en) | Piperazine-piperidine antagonists and agonists of the 5-HT1A receptor | |
EP1942947A4 (fr) | Polypeptides de fibronectine et methodes d'utilisation | |
IL178690A0 (en) | Peptidic vasopressin receptor agonists | |
EP2344519A4 (fr) | Fragments c-terminaux du peptide 1 de type glucagon (glp-1) | |
EP1709071A4 (fr) | Analogues peptidiques 1 semblables au glucagon a action de longue duree | |
EP1908778A4 (fr) | Fragments polypeptidiques d'exendine 4 et utilisation correspondante | |
ZA200802575B (en) | Trail receptor 2 polypeptides and antibodies | |
EP1713493A4 (fr) | Agonistes du recepteur (vpac2) du type peptides activant l'adenylate cyclase hypophysaire (pacap) et procedes pharmacologiques d'utilisation de ces agonistes | |
EP1896048A4 (fr) | Agonistes du recepteur (vpac2) du peptide activant l'adenylate cyclase hypophysaire (pacap) et leurs procedes pharmacologiques d'utilisation | |
ZA200705382B (en) | Antibodies against IL-13 receptor alpha 1 and uses thereof | |
PL370221A1 (en) | 2-oxazolamines and their use as 5-ht2b receptor antagonists | |
EP1970062A4 (fr) | Nouvel antagoniste cxcr4 et son utilisation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20071206 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20100701 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20110202 |